anticancer agent

Anticancer agent 3 (Compound 4) is an anticancer agent.

(S)-5-chloro-N-(1-((4-chlorophenyl)amino)-1-oxo-3-phenylpropan-2-yl)-2-hydroxybenzamide has antifungal and tuberculostatic activities.

Anticanceragent 260 (Compound 3g/4d) is an orally effective anticancer agent that inhibits the proliferation of cancer cells HCT-116, MIA-PaCa2, and MDA-MB231, with IC50 values of 98.7, 81.0, and 77.2 µg/mL, respectively. It also promotes ulcer formation and lipid peroxidation, and exhibits anti-inflammatory and analgesic activities.

Anticanceragent 263 (compound 7) is an effective anticancer agent. It binds with the G-quadruplex DNA (G4) sequence 22-mer Pu22 (a c-Myc DNA analog). As a structural modulator, Anticanceragent 263 significantly enhances the formation of protein α-helices and has the capacity to form a supramolecular network. Furthermore, Anticanceragent 263 exhibits no cytotoxicity.

Anticanceragent 257 (compound of formula (I)) is an anticancer agent that regulates Nur77 and Nurr1.

Anticanceragent 266 (Compound 3B) is an anticancer agent that inhibits the proliferation of tumor cells. It has an IC50 of 0.13 μM against the MCF-7 breast cancer cell line.

Anticanceragent 272 (Compound 2) is an anticancer agent demonstrating significant activity against bladder cancer cells (T-24) with an IC50 of 2.81 μM. It depletes glutathione (GSH) through a Fenton-like reaction, generating reactive oxygen species (ROS) and hydroxyl radicals (•OH), thereby inducing apoptosis and ferroptosis. Anticanceragent 272 enhances chemodynamic therapy (CDT) and promotes tumor cell death through mitochondrial dysfunction and autophagy. It holds potential for further research in bladder cancer.

Anticanceragent 176 (Compound 10α) is an anticancer agent that exhibits excellent in vitro cytotoxic activity against neuroblastoma, with an IC50 value of 6.3 μM.

Anticanceragent 187 (Compound 4) is an anticancer agent that targets sarcoma cells in tumor-bearing mouse models. It exhibits cytotoxicity against HepG2, Caco2, and MCF-7 cell lines.

Anticanceragent 189 (compound 4) is an anticancer agent that targets AKT1 to counteract the effects of CRC.

Anticancer agent 190 (compound 3e) is an inhibitor targeting KSP (Kinesin) and PI3Kδ, demonstrating efficacy against breast cancer.

Anticanceragent 198 (compound 18b) is an effective anticancer agent and a potential WRN protein inhibitor. It exhibits significant toxicity against K562 cells and WRN-overexpressing PC3 cells.

Anticanceragent 200 (6d) is a potential anticancer agent with activity against metastasis.

Anticanceragent 203 (compound 27) is an anticancer agent that exhibits cytotoxicity and holds potential for liver cancer research.

Anticanceragent 207 (compound 10b) is an effective anticancer agent. It binds to NRAS rG4 with a KD value of 2.31 µM. It exhibits cytotoxicity and reduces NRAS protein expression, demonstrating antitumor activity.

Anticanceragent 205 (compound 9) is an effective anticancer agent that binds to the G4-mtDNA target, inhibiting the replication, transcription, and translation of mtDNA (mitochondrial genome). It induces mitochondrial dysfunction, increases ROS production, and triggers DNA damage and cellular senescence. Anticanceragent 205 also promotes apoptosis and causes cell cycle arrest at the G0/G1 phase, showing potential for research in colorectal cancer.

Anticanceragent 227 (compound YNU-1c) is a potent anticancer agent with antiproliferative activity. It is capable of inducing apoptosis (apoptosis) and mitophagy (mitophagy).

Anticanceragent 202 (compound 3) acts as an anticancer agent.

Anticanceragent 224 (Compound 16) is an anticancer agent that effectively inhibits the growth of central nervous system (CNS) cancer, kidney cancer, and breast cancer cells, with GI50 values ranging from 0.6 to 12.8 μM.

Anticanceragent 212 (compound 10a) is a potent anticancer agent. Anticanceragent 212 exhibits cytotoxicity.

Anticanceragent 221 (Compound 4h) is an orally active anticancer and antioxidant agent. It exhibits cytotoxicity against cancer cells A549 (IC50=22.09 µg/mL) and MCF-7 (IC50=6.40 µg/mL) and induces apoptosis. It demonstrates antioxidant activity with an IC50 of 42.46 μM in the DPPH assay. In mouse models, Anticanceragent 221 shows antitumor efficacy against breast cancer.

Anticanceragent 222 (Compound 19) is an orally active anticancer agent that demonstrates significant anticancer activity against Huh7, FOCUS, SNU475, SNU182, HepG2, and Hep3B cells, with IC50 values ranging from 2.9 to 9.3 μM.

Anticanceragent 238 (compound 5) is an anticancer agent with a particularly strong binding affinity for the CDK-5 enzyme. It exhibits potent efficacy against HCT116 and MCF7 cells, with IC50 values of 13.46 µM and 16.43 µM, respectively.

Anticancer agent 7 (Example 5) is a potent anti-cancer compound with an IC50 value of 5 μM against H1650 lung cancer cells.